menu
    • menu
    [{"orgOrder":0,"company":"Abliva","sponsor":"Owl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"OWL-1410","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Owl Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Abliva \/ Owl Therapeutics"},{"orgOrder":0,"company":"Abliva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KL1333","moa":"NAD","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abliva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Abliva \/ Inapplicable"},{"orgOrder":0,"company":"Abliva","sponsor":"Pharming","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"KL1333","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Abliva","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Abliva \/ Pharming","highestDevelopmentStatusID":"8","companyTruncated":"Abliva \/ Pharming"},{"orgOrder":0,"company":"Abliva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KL1333","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Abliva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abliva \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Abliva

    Menu

    Abliva

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KL1333

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Pharming

                            Deal Size : $66.1 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pharming Pays $66M to for Abliva, Mitochondrial Disease Med

                            Details : The proposed acquisition will strengthen Pharming’s late-stage pipeline disease asset. Abliva’s lead product, KL1333, is being evaluated for mitochondrial diseases.

                            Product Name : KL1333

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 15, 2024

                            Lead Product(s) : KL1333

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Pharming

                            Deal Size : $66.1 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KL1333

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abliva Report Positive Interim Analysis of FALCON Study of KL1333 in Mitochondrial Disease

                            Details : Abliva lead product candidate KL1333 is being evaluated in the mid-stage clinical trial studies with patients for the treatment of Primary Mitochondrial Disease.

                            Product Name : KL1333

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 18, 2024

                            Lead Product(s) : KL1333

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OWL-1410

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : IND Enabling

                            Sponsor : Owl Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Owl Therapeutics Enters a Strategic Clinical Collaboration with Abliva to Advance NeuroSTAT® (OWL-1410) for T...

                            Details : Under the collaboration, Owl Therapeutics will advance Abliva's clinical development of NeuroSTAT (OWL-1410) with orphan drug designation, which is under development for the prevention and treatment of moderate to severe traumatic brain injury (TBI).

                            Product Name : NeuroSTAT

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            November 17, 2023

                            Lead Product(s) : OWL-1410

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : IND Enabling

                            Sponsor : Owl Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed

                            Abliva

                            Sweden arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KL1333

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abliva receives positive FDA feedback on its KL1333 development plant

                            Details : KL1333 is a potent modulator of the cellular levels of NAD, a central co-enzyme in the cell’s energy metabolism. The clinical KL1333 development plan will target patients with genetically confirmed MIDD-MELAS or KSS-CPEO spectrum disorders with multi-o...

                            Product Name : KL1333

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 07, 2020

                            Lead Product(s) : KL1333

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth